At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 21 enrolled
Drug / intervention
Zoledronic aciddrug
Likely dose
Zoledronic acid 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury
James J. Peters Veterans Affairs Medical Center·interventional·Posted Jan 23, 2014·Updated Mar 14, 2018
In Brief
A Phase 4 clinical trial evaluating Zoledronic acid for Disuse Osteoporosis. Completed, enrolled 21 participants across 1 site.
Detailed Summary
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisuse Osteoporosis
CountriesUnited States
CollaboratorsKessler Institute for Rehabilitation
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
Primary CompletionJul 2012
First PostedJan 2014
TodayJul 2026
First PostedJan 23, 2014
Enrollment StartMay 1, 2006
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 12.4 years ago
Interventions
Zoledronic aciddrug
At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.